Drugs / EVODENOSON
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01279083 | Jan → Nov 2011 | ocular hypertension, open-angle glaucoma | Santen Inc. | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EVODENOSON | ChEMBL registry synonym — accepted as the source's own label CHEMBL1950651 ↗ |
| Known as | ATL-313 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1950651 ↗ |
| Known as | Atl313, de-112 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1950651 ↗ |
| Known as | DE-112 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01279083 ↗ |
| Action | Activate | “Adenosine A2a receptor agonist” CHEMBL1950651 ↗ |
| Modality | Small molecule | — CHEMBL1950651 ↗ |
| Route | Topical | “Topical ocular solution” NCT01279083 ↗ |
| Target | ADORA2A | “Adenosine A2a receptor agonist” CHEMBL1950651 ↗ |